500 million men suffer from erectile dysfunction and premature ejaculation worldwide. Dicot is developing a modern potency drug with the ambition of creating a therapeutic drug that has a longer lasting effect and fewer side effects than those found on the market today.
News | 2024-06-06
LIB-01 appears to affect metabolic diseases. New patent application is submitted.
New results show that LIB-01 unexpectedly appears to influence several conditions and diseases that are commonly characterized by dysfunction in the body's metabolism. These include conditions such as obesity, diabetes and high blood pressure.
Read More >Dicot - the potency drug of tomorrow
![](https://img.youtube.com/vi/85roMsKfgTk/hqdefault.jpg)
News | 2024-04-24
Clinical phase 1 a success
The results from Dicot's phase 1 study have arrived, clearly showing that LIB-01 has a very good safety profile. Additionally, an effect signal emerged, resulting in improved erectile function among participants.
Read More >The ambition with LIB-01
- Longer duration
- Effective for everyone
- Minimal side-effects
![EU](/media/205142/flag_of_europe.png)